National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Axicabtagene ciloleucel (Yescarta®). HTA ID: 22066

Axicabtagene ciloleucel (Yescarta®) is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 27/09/2022
Rapid review completed 10/11/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axicabtagene ciloleucel compared with the current standard of care.